While maintaining its portfolio of marketed pharmaceuticals for hypertension, hyperlipidemia, and bacterial infections, Daiichi Sankyo is engaged in the development of treatments for thrombotic disorders and focused on the discovery of novel oncology and cardiovascular-metabolic therapies. more...
Like other research-based pharmaceutical companies, Daiichi Sankyo's engaged in high-risk/high-return research and development investments. more...
Besides the company's world headquarters in Tokyo, the Daiichi Sankyo Group has affiliates in almost 60 countries and in all continents. Its German and European base is located in Munich. more...
Daiichi Sankyo Europe has two production facilities, both approved by national and international authorities such as the US Food and Drug Administration (FDA), the European Medicines Agency (EMEA) more...
Latest news
-
Daiichi Sankyo Europe boosts net sales
Daiichi Sankyo Europe generated a strong increase in net sales during the first half of fiscal year 2011. more...
-
Ranbaxy to extend Daiichi Sankyo product reach to pharmacists across Italy
Begins distribution of Cardiovascular medicines Congescor and Lopresor more...
-
Daiichi Sankyo Launches LIXIANA® (edoxaban), a Direct Oral Factor Xa Inhibitor for the Prevention of Venous Thromboembolism after Major Orthopedic Surgery
First Direct Oral Factor Xa Inhibitor Available to Japanese Patients more...